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Background: Human epidermal growth factor receptor 2-in situ hybridization 
(HER2-ISH) is widely approved for diagnostic, prognostic biomarker testing of for-
malin-fixed paraffin-embedded tissue blocks. However, cytologic ISH analysis has a 
potential advantage in tumor samples such as pleural effusion and ascites that are dif-
ficult to obtain the histological specimens. Our aim was to evaluate the clinical reli-
ability of a novel rapid cytologic HER2 fluorescence ISH protocol (rapid-CytoFISH).
Materials and Methods: Using a new device, we applied a high-voltage/frequency, 
noncontact alternating current electric field to tissue imprints and needle rinses, which 
mixed the probe within microdroplets as the voltage was switched on and off (AC 
mixing). Cytologic samples (n = 143) were collected from patients with immunohis-
tochemically identified HER2 breast cancers. The specimens were then tested using 
standard dual-color ISH using formalin-fixed paraffin-embedded tissue (FFPE-tissue 
DISH) for HER2-targeted therapies, CytoFISH, and rapid-CytoFISH (completed 
within 4 h).
Results: All 143 collected cytologic specimens (50 imprinted cytology specimens 
from resected tumors and 93 liquid-based cytology specimens from needle rinses) 
were suitable for FISH analysis. The HER2/chromosome enumeration probe (CEP) 
17 ratios did not significantly differ between FFPE-tissue DISH and either CytoFISH 
protocol. Based on HER2 scoring criteria, we found 95.1% agreement between FFPE-
tissue DISH and CytoFISH (Cohen's kappa coefficient = 0.771 and 95% confidence 
interval (CI): 0.614–0.927).
Conclusion: CytoFISH could potentially serve as a clinical tool for prompt determi-
nation of HER2 status in breast cancer cytology. Rapid-CytoFISH with AC mixing 
   | 587WATANABE ET Al.
1 |  INTRODUCTION
Human epidermal growth factor receptor 2 (HER2) is an 
important prognostic and predictive biomarker in breast can-
cer.1,2 Amplification of HER2 is a primary driver mutation 
that occurs in approximately 20% of breast cancers and is 
associated with a poor prognosis in untreated patients.2,3 
Because HER2-targeted agents are an effective therapeutic 
approach for patients with overexpressed HER2 advanced/
metastatic breast cancer,2-7 HER2 levels should be assessed 
in all breast cancers. The commonly used techniques to de-
termine HER2 status are immunohistochemistry (IHC) and 
in situ hybridization (ISH).
HER2-ISH is a validated, reproducible method that is 
widely approved for diagnostic, prognostic biomarker test-
ing of formalin-fixed, paraffin-embedded tissue blocks 
(FFPE).8 However, it is associated with several limitations: 
1) the FFPE procedure involves the use of toxic formalin; 
2) the fixation and paraffin embedding process can be time 
consuming; and 3) the subsequent probe hybridization takes 
an additional 14–18 hours. As a result, it may take several 
days to assess HER2 status when using the conventional 
ISH procedure with FFPE. Moreover, because nearly all 
hospitals outsource performance of these assays, time-con-
suming ISH can delay the treatment intervention for pa-
tients with advanced breast cancer for as long as several 
weeks. In contrast, cytology enables same-day diagnosis, 
which decreases patient anxiety and facilitates treatment 
planning. In addition, cytological techniques, including 
flow cytometric analysis of DNA ploidy, immunocytology, 
and ISH for cancer detection, are being increasingly ap-
plied to facilitate the identification of neoplastic cells for 
molecular diagnoses.9 In breast cancer, for example, use of 
cytologic specimens for fluorescence ISH (FISH) to eval-
uate HER2 status revealed that FISH analysis of cytologic 
specimens produced more accurate HER2/chromosome 
enumeration probe (CEP) 17 signal ratios and HER2 copy 
numbers than histological specimens, as CEP17 is easily 
lost during histological sectioning.9-15 Another potential 
advantage of cytologic FISH is that it is difficult to obtain 
histological tumor specimens from some metastatic sites, 
such as plural effusion and cerebrospinal fluid. Moreover, 
a rapid 1-day HER2-ISH protocol for breast cancer cytol-
ogy is not yet available to diagnosticians/surgeons.
We have been developing a rapid-IHC/ISH that makes use of 
an alternating current (AC) electric field to facilitate the reagent 
reaction, and have reported its usefulness for molecular target 
detection in lung cancer, breast cancer, and brain tumors.16-19 
The device reduces the time required for IHC/ISH as well as 
the amount of reagent required for these analyses. This device 
applies a high-voltage, low-frequency, or high-frequency AC 
electric field to the sections. The resultant coulomb force stirs 
the diluted solution within microdroplets on the sections be-
cause the voltage is switched on and off at specific intervals. It 
increases the opportunity for antibody–antigen or DNA probe-
gene contact (AC mixing). This rapid-IHC method enables rapid 
detection of target cells in frozen sections and cytological sam-
ples, and can provide us with an intraoperative diagnosis within 
20 minutes.16,17 As a further application, we demonstrated that 
rapid-ISH with AC mixing can be used to detect HER2 ampli-
fication within 6 hours in breast cancer patients 20,21 and can 
detect Anaplastic lymphoma kinase break-apart hybridization 
within 4.5 hours in lung cancer patients.22,23 Moreover, in our 
earlier HER2 rapid-ISH study using FFPE, we obtained 98.8% 
agreement between amplification status detected with conven-
tional ISH and our new rapid-ISH.20 Although the rapid-ISH 
with AC mixing still has limitations, we anticipate that this 
technique will be applicable in multiple settings.
Cytologic specimens also have a potential advantage for 
evaluating HER2 status, especially in tumor samples such as 
serous effusion in the body cavity that are difficult to ob-
tain FFPE tissue. Moreover, cytology can be useful because 
same-day diagnosis decreases patient anxiety and facilitates 
prompt treatment, while the ISH procedure with FFPE in our 
earlier HER2 rapid-ISH study is time consuming by the par-
affin embedding process. In the present study, we evaluated 
the clinical utility and reliability of a novel rapid cytologic 
HER2 FISH protocol within 1 day (rapid-CytoFISH).
2 |  MATERIALS AND METHODS
2.1 | Patients
All experimental protocols were approved by the institutional 
review board at Akita University Hospital (Permit number: 
1282 and 1408), and written informed consent was obtained 
from all patients. Breast cancer samples were collected through 
will enable cancer diagnoses and HER2 status to be determined on the same day a 
patient comes to a clinic or hospital.
K E Y W O R D S
breast cancer, cytology, human epidermal growth factor receptor 2, in situ hybridization, noncontact 
alternating current electric field mixing
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core needle biopsy (CNB) and/or surgery before deciding final 
pathologic diagnosis at the Akita University Hospital, Akita 
Kousei Medical Center, Akita City Hospital, or Akita Red 
Cross Hospital between October 2018 and March 2020. The pa-
tients’ clinical characteristics are listed in Tables 1 and 2. Used 
in this study were 50 imprinted cytology samples from surgical 
specimens and 93 liquid-based cytology (LBC) samples that 
had been identified as HER2 0/(1+), (2+), or (3+) using IHC. 
In addition, the specimens were subjected to standard dual ISH 
T A B L E  1  Characteristics of patients from whom surgical 
cytology specimens were collected
Number of patients 50

















Ductal carcinoma in situ 1
Invasive ductal carcinoma 38















T A B L E  2  Characteristics of patients from whom liquid-based 
cytology specimens were collected
Number of patients 93
























Ductal carcinoma in situ 4
Invasive ductal carcinoma 78















Abbreviations: ER, estrogen receptor; IHC, immunohistochemistry; PgR, 
progesterone receptor.
*Sites of metastasis were overlapping for patients. 
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using FFPE tissue (FFPE-tissue DISH) using the ZytoVision 
manual protocol, or using an automated slide stainer. FFPE-
tissue DISH for HER2 was performed to determine whether to 
treat with HER2-targeted therapies.
2.2 | Samples and preparation
Using standard histological techniques, CNB and surgical spec-
imens were fixed in 10% formalin, embedded in paraffin, and 
stained using hematoxylin and eosin (HE) staining, IHC, and 
DISH. Imprinted cytology slides were obtained from resected 
breast cancer samples and were immediately fixed in 95% etha-
nol until they were used. LBC from CNB rinse samples were 
carried out using the concentration method with BD CytoRich 
systems Red (BD Franklin Lakes, NJ, USA), which involved 
rinsing the needle in a proprietary preservative solution. Both 
types of sample were re-fixed in Carnoy's Solution for 15 min-
utes and 10% formalin for 5 minutes prior to FISH.
2.3 | Immunohistochemistry
HER2-IHC with a rabbit anti-HER2/neu (4B5) monoclonal an-
tibody (Roche Diagnostics, Penzberg, Germany) as the primary 
antibody was performed using a BenchMark XT Staining Platform 
(Ventana Medical Systems, Tucson, AZ) with an automatic stain-
ing protocol. HER2-IHC were performed on all samples.
2.4 | Dual-color in situ hybridization (DISH)
Manual DISH was performed using a DNA-specific dual-
color probes ZytoDot2C SPEC HER2/CEN 17 Probe Kit 
(ZytoVision, Bremerhaven, Germany), or INFORM HER2 
Dual ISH DNA Probe Assays were performed on a BenchMark 
XT Staining Platform (Ventana Medical Systems, Tucson, 
AZ) according to the manufacturer's instructions.
2.5 | New rapid cytological fluorescence 
in situ hybridization (rapid-CytoFISH) 
using noncontact alternating current electric 
field mixing
After mounting a temperature control unit on our device, we 
used the prototype for rapid-ISH, which we described in ear-
lier reports.20-23 The theory behind AC electric field mixing 
and the method for its application were described in detail 
previously (Figure 1).16-23 Briefly, we use a device to apply 
F I G U R E  1  Rapid in situ hybridization device is used to apply a high-voltage, high-frequency alternating current electric field. (A) The 
prototype device mounting a temperature control unit. (B) Schema of the stir within a microdroplet as the voltage is switched on and off. The 
resultant coulomb force stirs the microdroplets on the sections, which increases the opportunity for DNA probe-gene contact (AC mixing) because 
the voltage is switched on and off at specific intervals
590 |   WATANABE ET Al.
an AC electric field to the sections. This causes the DNA 
probes in microdroplets to be mixed without a stirrer as the 
voltage is switched on and off at regular intervals.
HER2 CytoFISH was performed on cytological sam-
ples using a Histra-HER2 FISH kit (In Vitro Diagnostics, 
JOKOH, Shizuoka, Japan). After mounting an insoluble 
label cover with a 1-cm diameter hole in the center (SLS/E-
bar rabel II, Roche Diagnostics, Penzberg, Germany) on 
each microscope slide, 10 µl of HER2/neu rhodamine DNA 
probe and Ch-17 fluorescein DNA probe (Histra-HER2 
FISH kit, In Vitro Diagnostics, JOKOH, Shizuoka, Japan) 
were applied evenly. Thereafter, 40  µl of HAIKORU-
K140N (KANEDA, Japan), which is a very low viscosity 
liquid paraffin, were added as an oil cover for preventing 
probe evaporation. The slide was then placed between the 
electrodes, and a high-voltage (4.5  KV, offset 2.4  KV)/
frequency (90  Hz) AC current was applied. There was a 
distance of 7.0 mm between the slide and electrode plates, 
and the current was applied for 180 minutes at 37°C (rap-
id-CytoFISH protocol), as compared to 14–18  hours of 
hybridization in the standard CytoFISH protocol. Finally, 
the slides were counterstained with 10  µl of 4,6-diamidi-
no-2-phenylindole dihydrochloride (DAPI) and evaluated 
using fluorescence microscopy.
Table 3 summarizes each procedure required for ISH. The 
HER2 amplification based on the dual-probe HER2/CEP17 
ratio with an average HER2 copy number and signals/cell 
were evaluated using the ASCO/CAP scoring criteria includ-
ing the updated 2018 guideline modifications24 with both the 
standard FISH and CytoFISH protocols.
2.6 | Statistical analysis
Statistical analysis was performed using JMP IN 14.2.0 soft-
ware (SAS Institute, Cary, NC, USA). Differences among 
the groups were compared using the Dunnett's multiple 
comparison test. Cohen's kappa coefficient was used to assess 
the agreement of 4x2 contingency tables between protocols.
3 |  RESULTS
HER2 scoring using IHC and FFPE-tissue DISH was per-
formed with all specimens collected (50 imprinted cytology 
and 93 LBC samples) from 143 breast cancer patients. Using 
IHC, 49 specimens were scored 0, 49 were scored (1+), 31 
were scored (2+), and 14 were scored (3+). The HER2 status 
of the specimens that were HER2 FFPE-tissue DISH nega-
tive or positive were similarly evaluated using CytoFISH. 
The patient characteristics, including HER2/CEP17 ratios 
determined using CytoFISH, are listed in Tables 1 and 2. All 
of the cytologic specimens were suitable for FISH analysis.
The HER2/CEP17 ratios did not significantly differ be-
tween standard FFPE-tissue DISH and the two CytoFISH 
protocols (Figure 2, p > 0.05). Likewise, the HER2/CEP17 
ratios did not significantly differ if dividing group by the ratio 
<2 or ≥2, if extracting the ductal carcinoma in situ (DCIS) 
group, if dividing groups according to HER2-IHC status 
0/1+, 2+, or 3+, respectively. Representative examples of 
FISH on cytologic specimens are shown in Figure 3. HER2/
CEP17 signals were observed in 142 specimens (99.3%) 
when FFPE-tissue DISH was used for staining, in 139 spec-
imens (97.2%) when CytoFISH was used, and in 139 spec-
imens (97.2%) when rapid-CytoFISH with AC mixing was 
used. In addition, polysomy in CEP17 was detected in 10.5% 
(10 of 95 cases) of HER2 0/1+ patients, 23.3% (7 of 30 cases) 
in of HER2 2+ patients, and 50% (7 of 14 cases) of HER2 3+ 
patients. Two HER2-IHC 2+ cases showed HER2-ISH di-
agnostic mismatching between the conventional FFPE-tissue 
DISH and CytoFISH because of CEP17 polysomy.
Finally, we divided each of the 143 samples into 
three parts and performed standard FFPE-tissue DISH, 
CytoFISH, and rapid-CytoFISH with AC mixing. Table 4 
Protocol Conventional CytoFISH Rapid-CytoFISH















14–18 h (37°C) 14–18 h (37°C) 180 min,
AC mixing
Washing slides and other 
steps
8 min 8 min 8 min
Total time 20 h 18 h 3 h 46 min
Abbreviation: AC, alternating current electric field.
T A B L E  3  Procedural details for 
conventional FISH and CytoFISH
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shows the HER2 status of each sample based on the HER2/
CEP17 ratio and the average HER2 copy number. We found 
95.1% agreement between FFPE-tissue DISH and the two 
CytoFISH protocols (Cohen's kappa coefficient  =  0.771, 
and 95% confidence interval (CI): 0.614–0.927). When 
using imprinted cytology, we found 92.0% agreement 
between FFPE-tissue DISH and the CytoFISH protocols 
(Cohen's kappa coefficient  =  0.633 and 95% CI: 0.312–
0.955). When using LBC, we found 96.8% agreement 
between FFPE-tissue DISH and the CytoFISH protocols 
(Cohen's kappa coefficient  =  0.847 and 95% CI: 0.687–
1.000). Thus, diagnoses obtained using the new CytoFISH 
protocols, with and without AC mixing, were nearly equal 
to those obtained with standard FFPE-tissue DISH. In just 
one discrepancy case (HER2-IHC 3+) between FFPE-
tissue DISH and CytoFISHs, HER2 amplification was seen 
only in invasive carcinoma in surgical FFPE specimen. 
This case diagnosed as invasive ductal carcinoma, HER2-
IHC 1+ by preoperative CNB, and demonstrated invasive 
ductal carcinoma with intratumoral heterogeneity.
4 |  DISCUSSION
In the present study, we demonstrated that for cytologic 
breast cancer samples, rapid-CytoFISH with AC mixing can 
be used to detect HER2 amplification within the same day, 
enabling clinicians get both a cancer diagnosis and the HER2 
result within 1  day. In addition, although rapid-CytoFISH 
provides a result more promptly (within 4 h) than standard 
FFPE-tissue DISH, specimens subjected to CytoFISH were 
very well stained due to the uniform distribution of the cells, 
superior nuclear chromatin morphology, and smaller amounts 
of cellular overlap and background debris. This makes the 
F I G U R E  2  Comparison of HER2/CEP17 ratios between standard FFPE-tissue DISH and the two CytoFISH protocols. (A) HER2/CEP17 
ratios in all samples, and if dividing group by the ratio <2 or ≥2, (B) HER2/CEP17 ratio in HER2-immunohistochemistry (IHC) 0/1+ samples, (C) 
in HER2-IHC 2+ samples, and (D) in HER2-IHC 3+ samples. There were no significant differences between the standard FFPE-tissue DISH and 
the new CytoFISH protocols using cytologic samples (p > 0.05, Dunnett's multiple comparison test)
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evaluation of HER2 gene amplification using CytoFISH po-
tentially more accurate than with standard ISH methods.
There are two main rapid diagnostic techniques that are 
used to quickly diagnose breast cancer in any hospital: imprint/
smeared cytology and frozen sections, both of which gener-
ally entail HE staining. Frozen sections are able to preserve 
the immune activity of the antigen during processing. They, 
therefore, exhibit greater reactivity for antigen-antibody bind-
ing than is seen with conventional paraffin sections, and the 
antigen retrieval step can be omitted. However, in situations 
where only a small amount of breast tumor is accessible, taking 
frozen sections may risk depleting the specimen and leaving an 
inadequate amount of tissue for subsequent IHC or molecular 
analysis. In contrast, imprint cytology can be done quickly and 
is more cost effective than frozen sections, and it requires less 
tissue for production of slides.25 Theoretically, our rapid-IHC 
and -ISH with AC mixing can be applied to both techniques.
At present, CNB represents the gold standard for tumor 
tissue sampling to evaluate breast lesions. This is because 
of its low rate inconclusive results and the large amount of 
histological and molecular information potentially available 
when clinicians are considering a cancer diagnosis, biomark-
ers status, or therapeutic options prior to surgery.26 CNB has a 
higher sensitivity (87% vs 74%) and specificity (98% vs 96%) 
F I G U R E  3  Detection of HER2 on cytology using the new CytoFISH protocols. (A) Gene amplification on imprinted cytology using 
CytoFISH. (B) Gene amplification on liquid-based cytology (LBC) using CytoFISH. (C) Gene amplification on imprinted cytology using rapid-
CytoFISH. (D) Gene amplification on LBC using rapid-CytoFISH. (E) Non-amplification on imprinted cytology using CytoFISH. (F) Non-
amplification on LBC using CytoFISH. (G) Non-amplification on imprinted cytology using rapid-CytoFISH. (H) Non-amplification on LBC using 
rapid-CytoFISH. CEP17 was labeled with Spectrum Green, and HER2 was labeled with Spectrum Orange (Magnification: 100×)
A B C D






0 49 Negative 49 Negative 48 Negative 48
Positive 0 Positive 0 Positive 0
Not evaluable 0 Not evaluable 1 Not evaluable 1
1+ 49 Negative 49 Negative 47 Negative 47
Positive 0 Positive 0 Positive 0
Not evaluable 0 Not evaluable 2 Not evaluable 2
2+ 31 Negative 30 Negative 28 Negative 28
Positive 1 Positive 2 Positive 2
Not evaluable 0 Not evaluable 1 Not evaluable 1
3+ 14 Negative 0 Negative 1 Negative 1
Positive 13 Positive 13 Positive 13
Not evaluable 1 Not evaluable 0 Not evaluable 0
Kappa value Standard 0.771 0.771
Abbreviation: FFPE; formalin-fixed paraffin-embedded.
T A B L E  4  HER2 results from standard 
FFPE-tissue DISH, CytoFISH, and Rapid-
CytoFISH in all 143 cytology samples
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than fine needle aspiration cytology (FNAC), and provides 
more material for grading tumors and for assessing predictive 
factors, such as the hormone receptor and HER2 status.26,27 
Nevertheless, additional cytology, including FNAC and LBC, 
can be useful because same-day diagnosis decreases patient 
anxiety and facilitates prompt treatment. For same-day di-
agnoses, cytopathologic diagnosis has advantages in that it 
is a less expensive, less traumatic, and quicker technique.27 
Alternatively, core wash cytology specimens can be prepared 
by washing the tissue contained in the CNB needle notch with 
saline or cell-preserving solution, and a preliminary diagno-
sis can be given to the patient. This is what was done in the 
present study as we attempted to investigate HER2 status. In 
addition, the cytopathologic diagnosis from serous effusion in 
the body cavity is the gold standard for determining whether 
or not there is cancer metastasis. We will need to determine 
the usefulness of cytologic specimens for HER2 FISH testing, 
especially for patients with tumors from which samples are 
difficult to obtain.
CEP17 abnormalities, including whole chromosome 
and gene copy number anomalies, allelic losses, and struc-
tural rearrangements, are common in breast cancer. CEP17 
polysomy is reportedly present in up to 68% of breast can-
cers.28,29 Cytologic specimens are applicable for estimating 
CEP17 polysomy. The distance between the CEP17 signal 
and the nearest nuclear membrane is significantly shorter 
than between the HER2 signal and the nuclear membrane. 
Because CEP17 is adjacent to the nuclear membrane, it may 
be lost during sectioning. Consequently, cytologic speci-
mens tend to yield lower HER2/CEP17 ratios, though they 
are more likely to indicate the “actual” copy numbers.15 The 
CEP17 gain is not due to isolated polysomy, but may instead 
be gains in the whole chromosome and strongly correlate 
with aneuploidy with gain of multiple chromosomes.30 
Although aneuploidy is associated with poor clinical out-
comes, irrespective of tumor grade, problems related to an-
euploidy and genomic heterogeneity are common among all 
high-throughput molecular profiling techniques, including 
ISH. The response to HER2-targeted therapy in patients 
with CEP17 abnormalities is controversial,31,32 and accurate 
assessment of the HER2/CEP17 signal ratio may be crucial 
for accurate determination of the prognosis of breast cancer 
patients in clinical practice. For that purpose, HER2 FISH 
testing of cytologic specimens, which evaluate whole cells 
may be more accurate than histologic specimens.
Current ASCO/CAP guidelines 24 do not provide guid-
ance regarding sample handling, fixation techniques, scor-
ing, or interpretation for use with whole cell cytologic 
preparations. The 2018 ASCO/CAP guideline focused 
update recommended the same optimal tissue handling 
requirements as before, and the only recommendation in cy-
tology is that cytology specimens must be fixed in formalin. 
Since tissue handling and fixation protocols are different 
for standard FFPE tissue sections and whole cell cytologic 
preparations, optimal methods will need to be established 
for sample handling for FISH. While it is true that HER2 
and CEP 17 copy numbers may be more accurate in whole 
nuclei than in the truncated nuclei present in standard FFPE 
tissue sections, further investigation will be needed to eval-
uate the optimal methods for cytologic sample handling.
Rapid-CytoFISH has several potential limitations. First, 
the disadvantage of cytologic ISH involves distinguishing in-
vasive areas from heterogeneity. Although there was just one 
such case in which HER2 results differed between the FFPE-
tissue DISH and CytoFISH in this study, this disadvantage 
highlights this limitation. That is, there is the potential for 
selection and possible allocation bias, which are the main 
pitfall of histological tissue comparison studies. Second, our 
study has the important potential confounding the effects of 
including DCIS and clinicians do not know how this might 
be avoided if imprint cytology of breast tissue is to be used 
for the determination of HER2 status. The important third 
limitation of this study is that there is very little information 
currently available from clinical trials to inform the interpre-
tation of HER2 FISH on whole cells and no guidelines on 
specimen processing, assay performance, interpretation, and 
cutoffs. Additional data, new assay performance criteria and 
cutoff data prior to any clinical use of this methodology in 
whole cells from breast tissue will be needed. Thus, future 
research is needed to provide the additional data required to 
complete this new diagnosing system.
In conclusion, we have shown that CytoFISH could po-
tentially serve as a clinical tool for prompt determination 
of HER2 status in breast cancer cytology. HER2 rapid-Cy-
toFISH preserves both the cellular architecture and nuclear 
morphology, and does not deplete the specimen available for 
subsequent molecular analysis. This technique facilitates rapid 
hybridization by taking advantage of the noncontact mixing 
effect of an applied AC electric field, which enables breast 
cancer diagnoses and the results of HER2 tests to be obtained 
on the same day the patient comes to a clinic or hospital.
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